In the original article, there was a mistake in the legend for Tables 2 and 4 as published. In these tables, the number of cows in each group were stated incorrectly. The correct legend appears below.
Table 4.
Plasma pharmacokinetic parameters for meloxicam from seven post-partum cows compared to five mid-lactation cows intravenously administered a single dose of meloxicam at 0.2 mg/kg.
| IV | Mid-lactation | Post-partum | P-value |
|---|---|---|---|
| Cmax (μg/mL) | 1.22 (0.92–1.55) | 1.06 (0.84–1.34) | 0.26 |
| Tmax (h) | 0.13 (0.08–0.19) | 0.23 (0.08–4.01) | 0.73 |
| Vd (L/kg) | 0.29 (0.24–0.35) | 0.31 (0.19–0.48) | 0.94 |
| CL (L/kg/h) | 0.03 (0.02–0.03) | 0.01 (0.009–0.02) | 0.009 |
| AUC∞ (h x μg/mL) | 8.26 (6.62–10.10) | 16.30 (6.18–31.75) | 0.009 |
| AUC%extrapolated | 1.65 (1.29–2.06) | 1.68 (−11.13–29.84) | 0.14 |
| λz (h−1) | 0.08 (0.08–0.09) | 0.04 (0.03–0.07) | 0.006 |
| AUMC∞ (h x μg/mL) | 93.33 (72.00–118.95) | 393.75 (115.22–3908.18) | 0.009 |
| MRT∞ (h) | 11.30 (10.44–12.19) | 24.16 (12.23–85.36) | 0.006 |
| T1/2 (h) | 8.23 (7.90–8.58) | 17.31 (8.59–64.05) | 0.006 |
| E | 0.008 (0.006–0.01) | 0.004 (0.003–0.006) | 0.009 |
Results are presented in geometric means and 95% confidence intervals. P-values are based on non-parametric Wilcoxon Rank Sums 2-sample normal approximation.
Parameters include maximum plasma concentration (Cmax), time of Cmax (Tmax), area under the curve extrapolated to infinity (AUC∞), area under the first momentum curve extrapolated to infinity (AUMC∞), area under the curve percent extrapolated (AUC%extrapolated), slope of terminal phase (λz), terminal half-life (T1/2), volume of distribution (Vd), mean residence time (MRT∞), and clearance (CL).
Table 2. Plasma concentrations (μg/mL) for meloxicam from seven post-partum cows compared to five mid-lactation cows that received intravenous administration of a single dose of meloxicam at 0.2 mg/kg. Results are presented as geometric means and 95% confidence interval.
Table 4. Plasma pharmacokinetic parameters for meloxicam from seven post-partum cows compared to five mid-lactation cows intravenously administered a single dose of meloxicam at 0.2 mg/kg. Results are presented in geometric means and 95% confidence intervals. P-values are based on non-parametric Wilcoxon Rank Sums 2-sample normal approximation.
In the original article, there was a mistake in Table 4 as published. In this table, the units for Vd should have been L/kg. The corrected Table 4 appears below.
In the original article, there was a mistake in Table 5 as published. In this table, the units for Vz/F should have been L/kg and the values for Vz/F were incorrectly reported as mL/kg. The corrected Table 5 appears below.
Table 5.
Plasma pharmacokinetic parameters for meloxicam from six post-partum cows matched to mid-lactation cows orally administered a single dose of meloxicam at 1.0 mg/kg.
| Oral | Mid-lactation | Post-partum | P-value |
|---|---|---|---|
| Cmax (μg/mL) | 1.45 (1.12–1.88) | 2.61 (1.79–3.67) | 0.02 |
| Tmax (h) | 10.48 (8.50–12.83) | 16.75 (12.25–22.42) | 0.02 |
| Vz/F (L/kg) | 0.39 (0.27–0.60) | 0.22 (0.17–0.33) | 0.02 |
| CL/F (L/kg/h) | 0.03 (0.02–0.04) | 0.01 (0.007–0.019) | 0.008 |
| AUC∞ (h x μg/mL) | 36.01 (24.29–51.02) | 82.82 (50.55–126.77) | 0.008 |
| AUC%extrapolated | 0.60 (−0.09–1.89) | 0.47 (0.17–0.89) | 0.69 |
| λz (h−1) | 0.07 (0.06–0.08) | 0.06 (0.05–0.07) | 0.05 |
| AUMC∞ (h x μg/mL) | 733.95 (394.66–1194.39) | 2287.61 (981.54–4354.35) | 0.008 |
| MRT∞ (h) | 20.38 (17.16–24.02) | 27.62 (21.56–34.90) | 0.05 |
| T1/2 (h) | 9.55 (8.26–10.99) | 12.28 (9.60–15.42) | 0.05 |
| F (%) | 87.2 | 101.6 | –* |
Results are presented in geometric means and range. P-values are based on non-parametric Wilcoxon Rank Sums 2-sample normal approximation.
Parameters include maximum plasma concentration (Cmax), time of Cmax (Tmax), area under the curve extrapolated to infinity (AUC∞), area under the curve percent extrapolated (AUC%extrapolated), area under the first momentum curve to infinity (AUMC∞), slope of terminal phase (λz), terminal half-life (T1/2), volume of distribution per fraction of drug absorbed (Vz/F), mean residence time (MRT∞), clearance per fraction of drug absorbed (CL/F), and absolute bioavailability (Fabs).
Statistical comparisons could not be made between treatment groups due individual animals receiving a single treatment and therefore clearance cannot be assumed to be consistent.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.